Infection Control & Hospital Epidemiology


Table 1. Patient Characteristics Characteristic


Ageb


Female Race


White Black Asian Other


Hispanic ethnicity Medical insurance Private insurer Medicarec


Public, non-Medicare No Insurance


Length of stayb ICU stay during hospitalization


Hospitalization in previous 12 months Baseline eGFR, mL/min/1.73m2 >90c


60–90c <60


Charlson comorbidity indexb OPAT diagnosis


Skin and soft tissue Bone/joint


Hardware associated Diabetic ulcer Endocarditis


Bacteremia/Endovascular


Bacteremia during hospitalization Bacterial pathogen treated in OPAT


Methicillin-resistant Staphylococcus aureus Vancomycin-resistant Enterococcusc Polymicrobial infection No Yes


Empiric therapyc


949


Vancomycin


(n=312), No. (%) 63.1 (14.3) 129 (41.4)


236 (75.6) 30 (9.6) 7 (2.2)


39 (12.5) 24 (7.7)


131 (42.0) 142 (45.5) 37 (11.9) 2 (0.6)


9.8 (7.4) 48 (15.4) 161 (51.6)


138 (44.2) 103 (33.0) 71 (22.8) 1.7 (1.7)


18 (5.8) 76 (24.3) 118 (37.8) 49 (15.7) 28 (9.0) 23 (7.4) 66 (21.2)


92 (29.5) 0 (0)


127 (40.7) 112 (35.9) 73 (23.4)


Daptomycin


(n=105), No. (%) 53.9 (17.8) 33 (31.4)


79 (75.2) 10 (9.5) 1 (1.0)


15 (14.3) 8 (7.6)


51 (48.6) 35 (33.3) 17 (16.2) 2 (1.9)


11.1 (9.9) 22 (21.0) 56 (53.3)


61 (58.1) 21 (20.0) 23 (21.9) 1.4 (1.7)


5 (4.7)


32 (30.5) 32 (30.5) 15 (14.3) 11 (10.5) 10 (9.5) 34 (32.4)


39 (37.1) 10 (9.5)


.02


45 (42.9) 48 (45.7) 12 (11.4)


.15 .23 .82 .02


.92 .08


P Valuea <.01 .08 .83


.09 .65


.02 .02


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140